444 related articles for article (PubMed ID: 29549159)
1. Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.
Segal NH; He AR; Doi T; Levy R; Bhatia S; Pishvaian MJ; Cesari R; Chen Y; Davis CB; Huang B; Thall AD; Gopal AK
Clin Cancer Res; 2018 Apr; 24(8):1816-1823. PubMed ID: 29549159
[No Abstract] [Full Text] [Related]
2. Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors.
Tolcher AW; Sznol M; Hu-Lieskovan S; Papadopoulos KP; Patnaik A; Rasco DW; Di Gravio D; Huang B; Gambhire D; Chen Y; Thall AD; Pathan N; Schmidt EV; Chow LQM
Clin Cancer Res; 2017 Sep; 23(18):5349-5357. PubMed ID: 28634283
[No Abstract] [Full Text] [Related]
3. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors.
Cohen EEW; Pishvaian MJ; Shepard DR; Wang D; Weiss J; Johnson ML; Chung CH; Chen Y; Huang B; Davis CB; Toffalorio F; Thall A; Powell SF
J Immunother Cancer; 2019 Dec; 7(1):342. PubMed ID: 31801624
[TBL] [Abstract][Full Text] [Related]
4. First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20
Gopal AK; Levy R; Houot R; Patel SP; Popplewell L; Jacobson C; Mu XJ; Deng S; Ching KA; Chen Y; Davis CB; Huang B; Fly KD; Thall A; Woolfson A; Bartlett NL
Clin Cancer Res; 2020 Jun; 26(11):2524-2534. PubMed ID: 32144134
[TBL] [Abstract][Full Text] [Related]
5. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
Hamid O; Chiappori AA; Thompson JA; Doi T; Hu-Lieskovan S; Eskens FALM; Ros W; Diab A; Spano JP; Rizvi NA; Wasser JS; Angevin E; Ott PA; Forgie A; Yang W; Guo C; Chou J; El-Khoueiry AB
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302562
[TBL] [Abstract][Full Text] [Related]
6. A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors.
Rosen LS; Wesolowski R; Baffa R; Liao KH; Hua SY; Gibson BL; Pirie-Shepherd S; Tolcher AW
Invest New Drugs; 2020 Feb; 38(1):120-130. PubMed ID: 30887250
[TBL] [Abstract][Full Text] [Related]
7. First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors.
Forero A; Bendell JC; Kumar P; Janisch L; Rosen M; Wang Q; Copigneaux C; Desai M; Senaldi G; Maitland ML
Invest New Drugs; 2017 Jun; 35(3):298-306. PubMed ID: 28050790
[TBL] [Abstract][Full Text] [Related]
8. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors.
Shapiro GI; Vaishampayan UN; LoRusso P; Barton J; Hua S; Reich SD; Shazer R; Taylor CT; Xuan D; Borghaei H
Invest New Drugs; 2017 Jun; 35(3):315-323. PubMed ID: 28070718
[TBL] [Abstract][Full Text] [Related]
9. Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab.
Li Y; Tan S; Zhang C; Chai Y; He M; Zhang CW; Wang Q; Tong Z; Liu K; Lei Y; Liu WJ; Liu Y; Tian Z; Cao X; Yan J; Qi J; Tien P; Gao S; Gao GF
Cell Rep; 2018 Oct; 25(4):909-920.e4. PubMed ID: 30355497
[TBL] [Abstract][Full Text] [Related]
10. Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors.
Tran B; Carvajal RD; Marabelle A; Patel SP; LoRusso PM; Rasmussen E; Juan G; Upreti VV; Beers C; Ngarmchamnanrith G; Schöffski P
J Immunother Cancer; 2018 Sep; 6(1):93. PubMed ID: 30253804
[TBL] [Abstract][Full Text] [Related]
11. Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
Udagawa H; Akamatsu H; Tanaka K; Takeda M; Kanda S; Kirita K; Teraoka S; Nakagawa K; Fujiwara Y; Yasuda I; Okubo S; Shintani M; Kosloski MP; Scripture C; Tamura T; Okamoto I
Lung Cancer; 2019 Sep; 135():145-150. PubMed ID: 31446987
[TBL] [Abstract][Full Text] [Related]
12. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.
Patnaik A; Kang SP; Rasco D; Papadopoulos KP; Elassaiss-Schaap J; Beeram M; Drengler R; Chen C; Smith L; Espino G; Gergich K; Delgado L; Daud A; Lindia JA; Li XN; Pierce RH; Yearley JH; Wu D; Laterza O; Lehnert M; Iannone R; Tolcher AW
Clin Cancer Res; 2015 Oct; 21(19):4286-93. PubMed ID: 25977344
[TBL] [Abstract][Full Text] [Related]
13. Axicabtagene Ciloleucel in Combination with the 4-1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11.
Jain MD; Miklos DB; Jacobson CA; Timmerman JM; Sun J; Nater J; Fang X; Patel A; Davis M; Heeke D; Trinh T; Mattie M; Neumann F; Kim JJ; To C; Filosto S; Reshef R
Clin Cancer Res; 2023 Oct; 29(20):4118-4127. PubMed ID: 37527011
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.
Johnson ML; Braiteh F; Grilley-Olson JE; Chou J; Davda J; Forgie A; Li R; Jacobs I; Kazazi F; Hu-Lieskovan S
JAMA Oncol; 2019 Jul; 5(7):999-1007. PubMed ID: 31145415
[TBL] [Abstract][Full Text] [Related]
15. Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab.
Chin SM; Kimberlin CR; Roe-Zurz Z; Zhang P; Xu A; Liao-Chan S; Sen D; Nager AR; Oakdale NS; Brown C; Wang F; Yang Y; Lindquist K; Yeung YA; Salek-Ardakani S; Chaparro-Riggers J
Nat Commun; 2018 Nov; 9(1):4679. PubMed ID: 30410017
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors.
Shimizu T; Seto T; Hirai F; Takenoyama M; Nosaki K; Tsurutani J; Kaneda H; Iwasa T; Kawakami H; Noguchi K; Shimamoto T; Nakagawa K
Invest New Drugs; 2016 Jun; 34(3):347-54. PubMed ID: 27000274
[TBL] [Abstract][Full Text] [Related]
17. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
Hassan R; Blumenschein GR; Moore KN; Santin AD; Kindler HL; Nemunaitis JJ; Seward SM; Thomas A; Kim SK; Rajagopalan P; Walter AO; Laurent D; Childs BH; Sarapa N; Elbi C; Bendell JC
J Clin Oncol; 2020 Jun; 38(16):1824-1835. PubMed ID: 32213105
[TBL] [Abstract][Full Text] [Related]
18. Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer.
Hong DS; Gopal AK; Shoushtari AN; Patel SP; He AR; Doi T; Ramalingam SS; Patnaik A; Sandhu S; Chen Y; Davis CB; Fisher TS; Huang B; Fly KD; Ribas A
Front Immunol; 2022; 13():897991. PubMed ID: 35983060
[TBL] [Abstract][Full Text] [Related]
19. First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.
Piha-Paul SA; Geva R; Tan TJ; Lim DW; Hierro C; Doi T; Rahma O; Lesokhin A; Luke JJ; Otero J; Nardi L; Singh A; Xyrafas A; Chen X; Mataraza J; Bedard PL
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389618
[TBL] [Abstract][Full Text] [Related]
20. Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma.
Huang J; Xu B; Mo H; Zhang W; Chen X; Wu D; Qu D; Wang X; Lan B; Yang B; Wang P; Zhang H; Yang Q; Jiao Y
Clin Cancer Res; 2018 Mar; 24(6):1296-1304. PubMed ID: 29358502
[No Abstract] [Full Text] [Related]
[Next] [New Search]
